Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
ImmunityBio, Inc. announced that its pivotal randomized BCG-naive non-muscle invasive bladder cancer (NMIBC) trial has demonstrated sufficient statistical power to detect clinically meaningful differences between the Anktiva® plus BCG treatment regimen and BCG alone.

ImmunityBio, Inc. announced that its pivotal randomized BCG-naive non-muscle invasive bladder cancer (NMIBC) trial has demonstrated sufficient statistical power to detect clinically meaningful differences between the Anktiva® plus BCG treatment regimen and BCG alone.

老虎证券老虎证券2026/03/26 11:56
Show original
The company also confirmed that the supplemental Biologics License Application (BLA) for the therapy is progressing as planned, with a target completion in 2026.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AON plans to acquire USI for 17 billion USD, aiming at the SME insurance brokerage market.

According to informed sources, AON.US is close to reaching a deal valued at around $17 billion, including debt, to acquire insurance brokerage USI from private equity firm KKR.

智通财经2026/08/31 00:16
AON plans to acquire USI for 17 billion USD, aiming at the SME insurance brokerage market.